Home > Boards > US Listed > Biotechs > Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics presents clinical data on Selinexor (KPT-330)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mlkrborn Member Profile
 
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting PR Newswire (US) - 12/1/2020 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/1/2020 7:06:44 AM
Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5... PR Newswire (US) - 12/1/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2020 4:18:14 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 11/30/2020 4:13:39 PM
Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned ... PR Newswire (US) - 11/25/2020 7:00:00 AM
Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meet... PR Newswire (US) - 11/20/2020 10:30:00 AM
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet PR Newswire (US) - 11/12/2020 7:06:00 PM
Karyopharm to Participate at Jefferies 2020 Virtual London Healthcare Conference PR Newswire (US) - 11/10/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2020 4:10:15 PM
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Mee... PR Newswire (US) - 11/4/2020 1:16:00 PM
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire (US) - 11/3/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/2/2020 4:11:32 PM
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress PR Newswire (US) - 11/2/2020 4:05:00 PM
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Pati... PR Newswire (US) - 11/2/2020 4:01:00 PM
Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020 PR Newswire (US) - 10/26/2020 7:00:00 AM
Karyopharm Therapeutics Selects MediSpend's Transparency Solution PR Newswire (US) - 10/20/2020 10:00:00 AM
Replimune Appoints Tanya Lewis to the Board of Directors GlobeNewswire Inc. - 10/19/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 6:00:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 5:57:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/14/2020 5:55:32 PM
Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory... PR Newswire (US) - 10/6/2020 8:00:00 AM
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire (US) - 10/1/2020 4:05:00 PM
Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Cong... PR Newswire (US) - 9/14/2020 9:42:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2020 8:49:56 AM
mlkrborn   Wednesday, 01/22/14 01:17:30 PM
Re: None
Post # of 126 
Karyopharm Therapeutics presents clinical data on Selinexor (KPT-330) in colorectal cancer from ongoing Phase 1 study and preclinical data on novel PAK4 inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium; Data demonstrate preliminary evidence of anti-tumor activity of oral selinexor in colorectal cancer patients (KPTI) :

Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients
Potential Anti-Proliferative Activity of Novel PAK4 Inhibitor Seen in Preclinical Pancreatic Cancer Model

Co announced data from two poster presentations at the American Society of Clinical Oncology (TATD) 2014 Gastrointestinal (:GI) Cancers Symposium that took place January 16-18 in San Francisco, California.

The data presented included an update (as of December 16, 2013) from the ongoing Phase 1 study of oral Selinexor in solid tumors that show preliminary evidence of antitumor activity in metastatic colorectal cancer (:CRC) patients. Additionally, data were presented on novel, oral p21-activated kinase 4 (PAK4) inhibitors that show anti-proliferative activity and tolerability in a preclinical pancreatic cancer model.

"We are very pleased with these preliminary results showing that single agent oral Selinexor has the potential to provide disease control in a subset of patients with heavily pretreated CRC. We are currently continuing our Phase 1 dose expansion cohorts and expect to report more data at the annual ASCO conference in June," stated Sharon Shacham, Ph.D., founder, Chief Scientific Officer and President of Karyopharm. "In addition, the preliminary preclinical data on our compounds that selectively inhibit PAK4 support our continued development of these potential therapies towards first-in-human studies."

8:35 am Hemispherx Biopharma analysis of new data on protection from pulmonary damage associated with infection by highly pathogenic influenza virus (HEB) :

Co announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21, 2014 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-a Administered to the Buccal Mucosa." This presentation is a collaborative project conducted at Viroclinics, Rotterdam, an internationally recognized research entity for the study of both seasonal and pandemic influenza viruses. The biohazard facilities are directed by Prof. Albert D.M.E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza.
Thus, both H5N1 influenza virus (the subject of collaboration with the Osterhaus group) and H7N9 influenza virus (the subject of ongoing collaboration with Prof. J. Richt's group at the Center of Excellence for Emerging and Zoonotic Animal Diseases (:CEEZAD), Kansas State University (please see Expert Review of Anti-infective Therapy (online edition, pages 1-5, 2014) are susceptible to Alferon N treatment in various model systems.
Both H5N1 influenza virus and H7N9 influenza virus have recently lead to an increased incidence of clinical disease in various parts of the world.
The new study shows the importance of the interferon induced pathways in controlling influenza viral infection. No deaths were observed in individuals with the wildtype genotype, compared to a 33% mortality rate in patients with the dysfunctional interferon pathway genotype.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences